O‘zbekiston кardiologiyasi 2-jild 2-son (2025) · 110-121-betlar

Short and Medium-term Efficacy and Safety of “Sinotech+” (Uzbekistan) Stent in Primary Stenting for Patients with Acute Coronary Syndrome with ST-Segment Elevation

Фозилов, Хуршид, Атамуратов, Бахтиёр, Юлдашов, Бахтиёр, Fozilov, Xurshid, Atamuratov, Baxtiyor, Yuldashov, Baxtiyor, Fozilov, Khurshid, Atamuratov, Bakhtiyor, Yuldashov, Bakhtiyor

Manbada oʻqish PDF

Annotatsiya

Aim. To evaluate the efficacy and safety of the Uzbekistan-manufactured “Sinotech+” stent during primary percutaneous coronary intervention (pPCI) in patients presenting with ST-elevation acute coronary syndrome (STEMI). Materials and methods. The study was conducted at the X-ray Endovascular Treatment Department of Cardiovascular Diseases at the RSSPMCC. Between January and June 2025, all 31 patients diagnosed with STEMI underwent pPCI procedures. "Sinotech+" stents were implanted in 17 patients (54.8%), while "Resolute Integrity" stents were implanted in 14 patients (45.2%). Patients who received "Sinotech+" stent implantation were analyzed. Results. Coronary lesion distribution was as follows: single-vessel disease in 5 patients (29.4%), two- vessel disease in 7 patients (41.2%), and multi-vessel disease in 5 patients (29.4%). Pre-procedural coronary flow assessment using the TIMI (Thrombolysis in Myocardial Infarction) perfusion scale revealed TIMI-0 flow in 9 patients (53%) and TIMI-1 flow in 8 patients (47%). Following pPCI, TIMI-3 flow was achieved in 14 patients (82.4%), while TIMI-2 flow was achieved in the remaining 3 patients (17.6%). These results demonstrated 100% technical success (stent deployment and vessel opening) and 82.4% angiographic success (achieving TIMI-3 flow), indicating high clinical efficacy of primary PCI using “Sinotech+” stents. Conclusion. The Uzbekistan-manufactured “Sinotech+” stent demonstrated high efficacy and safety in patients presenting with STEMI. No complications (thrombosis, restenosis, recurrent myocardial infarction, repeat revascularization) were observed during clinical follow-up.

STEMIpPCI“Sinotech+”TIMISTEMIpPCI“Sinotech+”TIMIO’KS-STbTOKA

Metadata manbasi: jurnal OAI-PMH arxivi · Sindex toʻliq matnni saqlamaydi, manbaga havola beradi.

Iqtibos olish

APA 7 
Фозилов, Хуршид, Атамуратов, Бахтиёр, Юлдашов, Бахтиёр, Fozilov, Xurshid, Atamuratov, Baxtiyor, Yuldashov, Baxtiyor, Fozilov, Khurshid, Atamuratov, Bakhtiyor & Yuldashov, Bakhtiyor (2025). Short and Medium-term Efficacy and Safety of “Sinotech+” (Uzbekistan) Stent in Primary Stenting for Patients with Acute Coronary Syndrome with ST-Segment Elevation. O‘zbekiston кardiologiyasi, 2(2), 110-121.
GOST R 7.0.5 
Фозилов, Хуршид, Атамуратов, Бахтиёр, Юлдашов, Бахтиёр, Fozilov, Xurshid, Atamuratov, Baxtiyor, Yuldashov, Baxtiyor, Fozilov, Khurshid, Atamuratov, Bakhtiyor, Yuldashov, Bakhtiyor Short and Medium-term Efficacy and Safety of “Sinotech+” (Uzbekistan) Stent in Primary Stenting for Patients with Acute Coronary Syndrome with ST-Segment Elevation // O‘zbekiston кardiologiyasi. 2025. Т. 2. № 2. С. 110-121.
BibTeX 
@article{хуршид2025,
  author  = {Фозилов, Хуршид and Атамуратов, Бахтиёр and Юлдашов, Бахтиёр and Fozilov, Xurshid and Atamuratov, Baxtiyor and Yuldashov, Baxtiyor and Fozilov, Khurshid and Atamuratov, Bakhtiyor and Yuldashov, Bakhtiyor},
  title   = {Short and Medium-term Efficacy and Safety of “Sinotech+” (Uzbekistan) Stent in Primary Stenting for Patients with Acute Coronary Syndrome with ST-Segment Elevation},
  journal = {O‘zbekiston кardiologiyasi},
  year    = {2025},
  volume  = {2},
  number  = {2},
  pages   = {110-121}
}
RIS 
TY  - JOUR
AU  - Фозилов, Хуршид
AU  - Атамуратов, Бахтиёр
AU  - Юлдашов, Бахтиёр
AU  - Fozilov, Xurshid
AU  - Atamuratov, Baxtiyor
AU  - Yuldashov, Baxtiyor
AU  - Fozilov, Khurshid
AU  - Atamuratov, Bakhtiyor
AU  - Yuldashov, Bakhtiyor
TI  - Short and Medium-term Efficacy and Safety of “Sinotech+” (Uzbekistan) Stent in Primary Stenting for Patients with Acute Coronary Syndrome with ST-Segment Elevation
JO  - O‘zbekiston кardiologiyasi
PY  - 2025
VL  - 2
IS  - 2
SP  - 110
EP  - 121
ER  -